Clinical and prognostic significance of coagulation assays in melanoma

The activation of coagulation and fibrinolysis is frequently found among cancer patients. Such tumors are considered to be associated with a higher risk of invasion, metastases, and eventually worse outcome. The aim of this study is to explore the clinical and prognostic value of blood coagulation tests for melanoma patients. Pretreatment blood coagulation tests including prothrombin time (PT), activated partial thromboplastin time (APTT), prothrombin activity (PTA), international normalized ratio (INR), D-dimer (DD), fibrinogen (F) levels, and platelet (PLT) counts were carried out. This prospective study included 61 melanoma patients [stage I–II (n=10), stage III (n=14), stage IV (n=37), M1c (n=26) disease], and 50 healthy controls. It included 34 (56%) men, median age 53 years, range 16–88 years. Over half of the patients (54%) were in the metastatic stage and most of them (70%) had M1c. The plasma level of pretreatment blood coagulation tests including DD, F, APTT, INR levels, and PLT counts showed a statistically significant difference between the patient and the control group (P<0.001 for all, but P=0.049 for INR). The levels of INR, DD, F, and PLT counts were higher and APTT was lower in the melanoma group, whereas the PT and PTA levels did not show any significant difference. There was a significant association between PT, PTA, INR, and PLT levels and the age of the patient. Patients with node metastasis in M0 disease had higher levels of PTA and PLT counts (P=0.002 and 0.048, respectively) and lower levels of PT and INR (P=0.056 and 0.046, respectively). The M1c patients tended to have higher plasma F levels (437 vs. 297 mg/dl, P=0.055) than M1a and M1b patients. The 1-year survival rate for all patients was 70%. In association with distant metastasis, advanced metastatic stage (M1c), elevated lactate dehydrogenase, and erythrocyte sedimentation rate, only elevated plasma F levels had a significantly adverse effect on survival among the coagulation parameters (P=0.031). The 1-year survival rates for patients with high and normal F levels were 58 and 88%, respectively. In conclusion, changes in the coagulation-fibrinolytic system are often present in melanoma and elevation in the plasma F level is associated with decreased survival.

[1]  O. Wagner,et al.  High D-dimer levels are associated with poor prognosis in cancer patients , 2012, Haematologica.

[2]  A. Khorana.  Cancer and coagulation , 2012, American journal of hematology.

[3]  M. Bar‐eli,et al.  PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis. , 2011, Cancer research.

[4]  M. Barcinski,et al.  Malignant transformation in melanocytes is associated with increased production of procoagulant microvesicles , 2011, Thrombosis and Haemostasis.

[5]  A. Khorana.  Risk assessment and prophylaxis for VTE in cancer patients. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

[6]  W. Ruf,et al.  Tissue factor and cell signalling in cancer progression and thrombosis , 2011, Journal of thrombosis and haemostasis : JTH.

[7]  M. Bar‐eli,et al.  The Emerging Role of the Thrombin Receptor (PAR-1) in Melanoma Metastasis - a Possible Therapeutic Target , 2011, Oncotarget.

[8]  M. Bar‐eli,et al.  Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype , 2010, Proceedings of the National Academy of Sciences.

[9]  S. W. Schneider,et al.  The mechanism of melanoma-associated thrombin activity and von Willebrand factor release from endothelial cells. , 2010, The Journal of investigative dermatology.

[10]  R. Navab,et al.  From Melanocyte to Metastatic Malignant Melanoma , 2010, Dermatology research and practice.

[11]  A. Khorana,et al.  Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score. , 2010, Thrombosis research.

[12]  A. Khorana,et al.  Cancer, clots and consensus: new understanding of an old problem. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  N. Mackman,et al.  Role of Tissue Factor in Cancer , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Barcinski,et al.  Tumor-derived microvesicles modulate the establishment of metastatic melanoma in a phosphatidylserine-dependent manner. , 2009, Cancer letters.

[15]  L. G. Lima,et al.  Simultaneous tissue factor expression and phosphatidylserine exposure account for the highly procoagulant pattern of melanoma cell lines , 2009, Melanoma research.

[16]  C. Kessler.  The link between cancer and venous thromboembolism: a review. , 2009, American journal of clinical oncology.

[17]  M. Różalski,et al.  Cancer procoagulant (CP) analysis in human WM 115 malignant melanoma cells in vitro. , 2009, Thrombosis research.

[18]  R. White,et al.  Epidemiology of cancer-related venous thromboembolism. , 2009, Best practice & research. Clinical haematology.

[19]  J. Rak,et al.  Tissue factor in tumour progression. , 2009, Best practice & research. Clinical haematology.

[20]  Shaker A Mousa,et al.  The role of tissue factor pathway inhibitor in tumor growth and metastasis. , 2007, Seminars in thrombosis and hemostasis.

[21]  A. Falanga.  Thrombophilia in cancer. , 2005, Seminars in thrombosis and hemostasis.

[22]  M. Oya,et al.  High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. , 2001, Japanese journal of clinical oncology.

[23]  T. Bugge,et al.  Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. , 2000, Blood.

[24]  D. Berry,et al.  Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Yoshida,et al.  Prognostic significance of plasma D-dimer levels in patients with lung cancer. , 1997, Thorax.

[26]  P. Mannucci,et al.  Hypercoagulability and hyperfibrinolysis in patients with melanoma. , 1996, Thrombosis research.

[27]  W. Konigsberg,et al.  Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S. Karpatkin,et al.  Role of Platelets, Thrombin, Integrin llb-llla, Fibronectin and Von Willebrand Factor on Tumor Adhesion in Vitro and Metastasis in Vivo , 1995, Thrombosis and Haemostasis.

[29]  P. Mannucci,et al.  Changes in fibrinolysis in patients with localized tumors. , 1990, European journal of cancer.

[30]  P. Mannucci,et al.  Early presence of activated ('exhausted') platelets in malignant tumors (breast adenocarcinoma and malignant melanoma). , 1989, European journal of cancer & clinical oncology.

[31]  L. Heilmann,et al.  Hemorheologic variables in breast cancer patients at the time of diagnosis and during treatment , 1988, Cancer.

[32]  S. Karpatkin,et al.  Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. , 1988, The Journal of clinical investigation.

[33]  P. Mannucci,et al.  Hemostatic alterations are unrelated to the stage of tumor in untreated malignant melanoma and breast carcinoma. , 1985, European journal of cancer & clinical oncology.

[34]  F. Rickles,et al.  Activation of blood coagulation in cancer: Trousseau's syndrome revisited. , 1983, Blood.

[35]  P. Sandset,et al.  Thrombosis Research--affiliation with the European Thrombosis Research Organization (ETRO). , 2010, Thrombosis research.

[36]  I. Macdonald,et al.  Effect of anti-fibrinolytic therapy on experimental melanoma metastasis , 2008, Clinical & Experimental Metastasis.

[37]  P. Salama.  [Thrombosis and cancer]. , 2004, Anales del sistema sanitario de Navarra.

[38]  J. Degen,et al.  Fibrinogen and tumor cell metastasis. , 2001, Haemostasis.

[39]  O. Hoffmann,et al.  Perioperative development of a thrombogenic risk profile in patients with carcinomas of the breast: a cause of increased thrombosis. , 2000, European journal of gynaecological oncology.

[40]  E. Gabazza,et al.  Evaluating prethrombotic state in lung cancer using molecular markers. , 1993, Chest.

[41]  S. Karpatkin,et al.  Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. , 1991, The Journal of clinical investigation.